|Other Names||WD repeat domain phosphoinositide-interacting protein 3, WIPI-3, WD repeat-containing protein 45-like, WDR45-like protein, WD repeat-containing protein 45B, WIPI49-like protein, WDR45B, WDR45L, WIPI3|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13252a was selected from the N-term region of WDR45L. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Ubiquitously expressed. Highly expressed in heart, skeletal muscle and pancreas. Up-regulated in a variety of tumor tissues including ovarian and uterine cancers|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the WIPI or SVP1 family ofWD40 repeat-containing proteins. The protein contains seven WD40repeats that are thought to fold into a beta-propeller structurethat mediates protein-protein interactions, and a conserved motiffor interaction with phospholipids. The human genome containsseveral pseudogenes of this gene.
Proikas-Cezanne, T., et al. Oncogene 23(58):9314-9325(2004)Jeffries, T.R., et al. Mol. Biol. Cell 15(6):2652-2663(2004)Venter, J.C., et al. Science 291(5507):1304-1351(2001)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.